IndinavirJournal Citations

Medical Advocates
Indinavir (Crixivan)

Journal Citations

General Studies
Pharmacokinetics
Viral Dynamics
Resistance
Adverse Events
Diagnostics/Monitoring
Drug/Drug Interactions
Drug/Herbal Interactions
Adherence
Adult/Adolescent Treatment
Treatment Strategies

Indinavir Main Page Main New/Newsworthy Home Page

Last Update: January 08, 2018
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Perinatal Journal Data are integrated with Perinatal Conference Data in the Perinatal Data Page.
Pediatric Journal Data are integrated with Pediatric Conference Data in the Pediatric Data Page

General Studies

FULL-TeXT ARTICLE
Indinavir and atazanavir; comparison of predicted property by chemoinformatics technique and implication on renal problem in HIV infected patients.
Joob B, Wiwanitkit V.
J Nephropharmacol. 2016 Jan 21;6(1):21-22.
Paper
Differences in the Prediction of Area Under the Curve for a Protease Inhibitor Using Trough Versus Peak Concentration: Assessment Using Published Pharmacokinetic Data for Indinavir.
Srinivas NR.
Am J Ther. 2015 Aug 18.
Abstract

Indinavir and nelfinavir inhibit proximal insulin receptor signalling and salicylate abrogates inhibition: Potential role of the NFkappa B pathway.
Ismail WI, King JA, Anwar K, Pillay TS.
J Cell Biochem. 2013 Feb 5.
Abstract

Indinavir Pharmacokinetics during Different Phases of the Menstrual Cycle in HIV-Infected Women.
Frost CE, Adams J, Shelton M, et al
Clin Drug Investig. 2002;22(2):125-34.
Abstract

Pairwise additivity of energy components in protein-ligand binding: The HIV II protease-Indinavir case.
Ucisik MN, Dashti DS, Faver JC, Merz KM.
J Chem Phys. 2011 Aug 28;
Abstract

Lead expansion and virtual screening of Indinavir derivate HIV-1 protease inhibitors using pharmacophoric -
shape similarity scoring function.
Shityakov S, Dandekar T.
Bioinformation. 2010 Jan 20;4(7):295-9
Abstract

HIV protease inhibitors, indinavir or nelfinavir, augment antimalarial
action of artemisinin in vitro.
Mishra LC, Bhattacharya A, Sharma M, Bhasin VK.
Am J Trop Med Hyg. 2010 Jan;82(1):148-50
Abstract

Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and
indinavir and confers fitness advantage.
Soares EA, Santos AF, Gonzalez LM, et al
J Antimicrob Chemother. 2009 Aug 26.
Abstract

Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating
HAART.
Bertrand J, Treluyer JM, Panhard X,
Eur J Clin Pharmacol. 2009 May 14
Abstract

Relationship between P-glycoprotein activity measured in peripheral blood mononuclear cells and indinavir
bioavailability in healthy volunteers.
Bramuglia GF, Cortada CM, Curras V, et al
J Pharm Sci. 2008 May 27.
Abstract

Exploitation of HIV protease inhibitor Indinavir as a memory restorative agent in experimental
dementia
Sharma B, Singh N, Singh M, Jaggi AS.
Pharmacol Biochem Behav. 2008 Feb 12
Abstract

Evaluation of thermal stability of indinavir sulphate using diffuse reflectance infrared
spectroscopy.
Singh P, Premkumar L, Mehrotra R, et al
J Pharm Biomed Anal. 2008 Jan 6
Abstract

Indinavir influences biological function of dendritic cells and stimulates antifungal immunity.
Pericolini E, Cenci E, Gabrielli E, et al
J Leukoc Biol. 2008 Feb 5
Abstract

Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS,
particularly in resource-limited settings.
Cressey TR, Plipat N, Fregonese F, Chokephaibulkit K.
Expert Opin Drug Metab Toxicol. 2007 Jun;3(3):347-361.
Abstract
Indinavir: the forg
otten HIV-protease inhibitor. Does it still have a role?
Boyd M.
Expert Opin Pharmacother. 2007 May;8(7):957-64.
Abstract

Influence of body temperature on indinavir crystallization under loop of Henle conditions.
Salahuddin S, Kok DJ, Buchholz NN.
J Antimicrob Chemother. 2006 Nov 9
Abstract

Electrochemical methods for determination of the protease inhibitor indinavir sulfate in
pharmaceuticals and human serum.
Dogan B, Canbaz D, Ozkan SA, Uslu B.
Pharmazie. 2006 May;61(5):409-13.
Abstract

Association of total bilirubin with indinavir and lopinavir plasma concentrations in HIV-infected
patients receiving three different double-boosted dosing regimens.
Dicenzo R, Luque A, Larppanichpoonphol P, Reichman R.
J Antimicrob Chemother. 2006 Jun 7
Abstract

Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics
and response to highly active antiretroviral therapy.
Verstuyft C, Marcellin F, Morand-Joubert L, et al
AIDS. 2005 Dec 2;19(18):2127-2131.
Abstract

Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy.
King JR, Gerber JG, Fletcher CV, Bushman L, Acosta EP.
AIDS. 2005 Jul 1;19(10):1059-1063.
Abstract

The human immunodeficiency virus (HIV) protease inhibitor indinavir directly affects the
opportunistic fungal pathogen Cryptococcus neoformans.
Blasi E, Colombari B, Francesca Orsi C, et al
FEMS Immunol Med Microbiol. 2004 Oct 1;42(2):187-95
Abstract

Impact of Indinavir on the Quality of Life in Patients with Advanced HIV Infection Treated
with Zidovudine
and Lamivudine.
Coplan PM, Cook JR, Carides GW, et al
Clin Infect Dis. 2004 Aug 1;39(3):426-33
Abstract

Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or
indinavir-based triple combination HAART also containing lamivudine/zidovudine.
Cahn P, Vibhagool A, Schechter M, Soto-Ramirez L, et al
Curr Med Res Opin. 2004 Jul;20(7):1115-23.
Abstract

Analysis of the protease sequences of HIV-1 infected individuals after Indinavir monotherapy.
Sa-Filho DJ, Costa LJ, de Oliveira CF, et al
Clin Virol. 2003 Oct;28(2):186-202.
Abstract

Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes.
Gagne JF, Desormeaux A Perron S, et al.
Biochim Biophys Acta 2002 Feb 1;1558(2):198-210
Abstract

Pharmacokinetics

Pharmacokinetics of an Indinavir-Ritonavir-Fosamprenavir Regimen in Patients with Human
Immunodeficiency Virus.
Ofotokun I, Acosta EP, Lennox JL, et al
Pharmacotherapy. 2008 Jan;28(1):74-81.
Abstract

Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of
indinavir in HIV-infected patients.
Solas C, Simon N, Drogoul MP, et al
Br J Clin Pharmacol. 2007 May 22;
Abstract

Pharmacokinetics and Tolerability of a Combination of Indinavir, Lopinavir and Ritonavir in Multiply
Pretreated HIV-1 Infected Adults.
von Hentig N, Muller A, Rottmann C, et al
Eur J Med Res. 2006 Jun 30;11(6):236-44
Abstract

Pharmacogenetic Characteristics of Indinavir, Zidovudine, and Lamivudine Therapy
in HIV-Infected Adults: A Pilot Study.
Anderson PL, Lamba J, Aquilante CL,
J Acquir Immune Defic Syndr. 2006 Jun 19;
Abstract

Steady-State Pharmacokinetics and Tolerability of Indinavir-Lopinavir/R Combination Therapy in
Antiretroviral-Experienced Patients.
Antoniou T, Tseng AL, van Heeswijk RP, et al
Ther Drug Monit. 2005 Dec;27(6):779-781.
Abstract

Population pharmacokinetics of indinavir alone and in combination with ritonavir in
HIV-1-infected patients.
Kappelhoff BS, Huitema AD, Sankatsing SU,
Br J Clin Pharmacol. 2005 Sep;60(3):276-86.
Abstract

Pharmacokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule formulation
of Didanosine in healthy volunteers.
la Porte C, Verweij-van Wissen C, et al
J Clin Pharmacol. 2005 Feb;45(2):211-8.
Abstract

Pharmacokinetics of indinavir at 800, 600, and 400 milligrams administered with ritonavir
at 100 milligrams and efavirenz in ethnic chinese patients infected with human
immunodeficiency virus.
Lee LS, Panchalingam A, Yap MC, Paton NI.
Antimicrob Agents Chemother. 2004 Nov;48(11):4476-8.
Abstract

Population pharmacokinetics of indinavir in patients infected with human immunodeficiency
virus.
Csajka C, Marzolini C, Fattinger K, et al
Antimicrob Agents Chemother. 2004 Sep;48(9):3226-32.
Abstract

Differential diffusions of indinavir and lopinavir in genital secretions of human
immunodeficiency virus-infected women.
Launay O, Tod M, Louchahi K,et al
Antimicrob Agents Chemother. 2004 Feb; 48(2): 632-4.
Abstract

Indinavir alters sterol and fatty acid homeostatic mechanisms in primary rat hepatocytes
by increasing levels of activated sterol regulatory element-binding proteins and decreasing
cholesterol 7alpha-hydroxylase mRNA levels.
Williams K, Rao YP, Natarajan R,
Biochem Pharmacol. 2004 Jan 15;67(2):255-67.
Abstract

The HIV protease inhibitor Indinavir reduces immature dendritic cell transendothelial
migration.
Whelan KT, Lin CL, Cella M, et al
Eur J Immunol. 2003 Sep;33(9):2520-30.
Abstract

Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma.
Haas DW, Johnson B, Nicotera J, et al.
Antimicrob Agents Chemother. 2003 Jul;47(7):2131-7.
Abstract

Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in
HIV-infected Thai patients.
Burger D, Boyd M, Duncombe C, et al.
J Antimicrob Chemother 2003 Mar 28
Abstract

Population Pharmacokinetics and Pharmacodynamics of Efavirenz, Nelfinavir, and Indinavir:
Adult AIDS Clinical Trial Group Study 398.
Pfister M, Labbe L, Hammer SM, et al.
Antimicrob Agents Chemother 2003 Jan;47(1):130-137
Abstract

Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics.
Penzak SR, Acosta EP, Turner M, et al
J Clin Pharmacol 2002 Oct;42(10):1165-70
Abstract

Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations
Murata H, Hruz PW, Mueckler M.
AIDS 2002 Apr 12;16(6):859-863
Abstract

Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized,
placebo-controlled study.
Noor MA, Seneviratne T, Aweeka FT, Lo JC, et al.
AIDS 2002 Mar 29;16(5):F1-8
Abstract

The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir.
Kosel BW, Aweeka FT, Benowitz NL, et al.
AIDS 2002 Mar 8;16(4):543-50
Abstract

FULL-TEXT ARTICLE
Pharmacological Basis for Concentration-Controlled Therapy with Zidovudine, Lamivudine,
and Indinavir
Kakuda TN, Page LM, Anderson PL, et al.
Antimicrob Agents Chemother 2001 Jan;45(1); 236-242
Paper
FULL-TEXT ARTICLE
Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal
plasma.
van Praag RM, Repping S, de Vries JW, et al.
Antimicrob Agents Chemother 2001Oct;45(10):2902-2907
Paper

FULL-TEXT ARTICLE
Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy
volunteers.
Saah AJ, Winchell GA, Nessly ML, Seniuk MA, et al.
Antimicrob Agents Chemother 2001 Oct;45(10):2710-5
Paper

FULL-TEXT ARTICLE
Indinavir pharmacokinetics and pharmacodynamics in children with human
immunodeficiency virus infection.
Gatti G, Vigano' A, Sala N, Vella S, Bassetti M, Bassetti D, Principi N
Antimicrob Agents Chemother 2000 Mar;44(3):752-755
Paper

FULL-TEXT ARTICLE
Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus
type 1-infected children.
Burger DM, van Rossum AM, Hugen PW, et al.
Antimicrob Agents Chemother 2001 Mar;45(3):701-705
Paper

FULL-TEXT ARTICLE
Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV
Neurobehavioral
Research Center Group.
Letendre SL, Capparelli EV, Ellis RJ, McCutchan JA.
Antimicrob Agents Chemother 2000 Aug;44(8):2173-2175
Paper

FULL-TEXT ARTICLE
Pharmacological Basis for Concentration-Controlled Therapy with Zidovudine, Lamivudine,
and Indinavir
Kakuda TN, Page LM, Anderson PL, et al.
Antimicrob Agents Chemother 2001 Jan;45(1); 236-242
Paper

Viral Dynamics

Indinavir Plasma Concentration and Adherence Score Are Codeterminant of Early Virologic
Response in HIV-Infected Patients of the APROCO Cohort.
Duval X, Mentre F, Lamotte C, et al
her Drug Monit. 2005 Feb;27(1):63-70.
Abstract

Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments:
clinical correlations.
Lafeuillade A, Solas C, Halfon P, et al.
HIV Clin Trials 2002 Jan-Feb;3(1):27-35
Abstract

Drug/Drug Interactions

Indinavir/Fluvastatin

Lipid Lowering Therapy with Fluvastatin and Pravastatin in Patients with HIV Infection and
Antiretroviral Therapy: Comparison of Efficacy and Interaction with Indinavir.
Benesic A, Zilly M, Kluge F, et al
Infection. 2004 Aug;32(4):229-33.
Abstract

Indinavir/Lamivudine

Indinavir Alters the Pharmacokinetics of Lamivudine Partially via Inhibition of Multidrug and Toxin Extrusion Protein 1 (MATE1).
Li Q, Ye Z, Zhu P, et al Pharm Res. 2018 Jan 4;35(1):14.
Abstract

Indinavir/Pravastatin

Lipid Lowering Therapy with Fluvastatin and Pravastatin in Patients with HIV Infection
and Antiretroviral Therapy: Comparison of Efficacy and Interaction with Indinavir.
Benesic A, Zilly M, Kluge F, et al
Infection. 2004 Aug;32(4):229-33.
Abstract

Indinavir/Ritonavir

In-vitro crystallization of indinavir in the presence of ritonavir and as a function of pH.
Li LY, Rodriguez-Hornedo N, Heimbach T, Fleisher D.
J Pharm Pharmacol. 2003 May;55(5):707-11.
Abstract

Indinavir/Ritonavir/Calcium Channel Blockers

Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers.
Glesby MJ, Aberg JA, Kendall MA
Clin Pharmacol Ther. 2005 Aug;78(2):143-153.
Abstract

Indinavir/Ritonavir/Didanosine

Pharmacokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule
formulation of Didanosine in healthy volunteers.
la Porte C, Verweij-van Wissen C, et al
J Clin Pharmacol. 2005 Feb;45(2):211-8.
Abstract

Indinavir/Ritonavir/Rifampin

Pharmacokinetic Interaction between Rifampin and the Combination of Indinavir and
Low-Dose Ritonavir in HIV-Infected Patients.
Justesen US, Andersen AB, Klitgaard NA, et al.
Clin Infect Dis. 2004 Feb 1; 38(3): 426-9.
Abstract

Indinavir/Rifabutin

Indinavir and rifabutin drug interactions in healthy volunteers.
Kraft WK, McCrea JB, Winchell GA, et al
J Clin Pharmacol. 2004 Mar;44(3):305-13
Abstract

Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin.
Hamzeh FM, Benson C, Gerber J, et al
Clin Pharmacol Ther 2003 Mar;73(3):159-69
Abstract

Indinavir/Tenofovir/r

Pharmacokinetic Interaction between Indinavir and Darunavir
with Low-Dose Ritonavir in Healthy Volunteers.
Sekar V, Lefebvre E, De Marez T, et al
IntervAbstractirology. 2010 Mar 3;53(3):176-182.

Indinavir/Voriconazole

No clinically significant pharmacokinetic interactions between voriconazole and indinavir in
healthy volunteers.
Purkins L, Wood N, Kleinermans D, Love ER.
Br J Clin Pharmacol. 2003 Dec;56 Suppl 1:62-68
Abstract

Diagnostics/Monitoring

Simultaneous Quantitation of HIV-Protease Inhibitors Ritonavir, Lopinavir and Indinavir in Human Plasma
by UPLC-ESI-MS-MS.
Mishra TD, Kurani H, Singhal P, Shrivastav PS.
J Chromatogr Sci. 2012 May 4.
Abstract

Evidence-based Therapeutic Drug Monitoring for Indinavir
Barrail-Tran A, Taburet AM, Poirier JM.
Therapie. 2011 May-Jun;66(3):239-46.
Abstract

UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in
mouse serum and tissues.
Huang J, Gautam N, Bathena SP
JChromatogr B Analyt Technol Biomed Life Sci. 2011 Jul 1
Abstract

A liquid chromatography-tandem mass spectrometry assay for quantification of nevirapine,
indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir
and maraviroc in the plasma of patients infected with HIV.
Martin J, Deslandes G, Dailly E, et al
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Aug 3
Abstract

Drug/Herbal Interactions

Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis.
Mills E, Wilson K, Clarke M
Eur J Clin Pharmacol. 2005 Jan 22;
Abstract

Influence of goldenseal root on the pharmacokinetics of indinavir.
Sandhu RS, Prescilla RP, Simonelli TM, Edwards DJ.
Clin Pharmacol. 2003 Nov;43(11):1283-8
Abstract

Resistance

A Contribution to the Drug Resistance Mechanism of Darunavir, Amprenavir, Indinavir, and Saquinavir Complexes with HIV-1 Protease Due to Flap Mutation I50V: A Systematic MM-PBSA and Thermodynamic Integration Study.
Leonis G, Steinbrecher TB, Papadopoulos MG.
J Chem Inf Model. 2013 Jul 8
Abstract
Indinavir resistance evolution in one human immunodeficiency virus type 1 infected patient
revealed by single-genome amplification.
Geng QM, Li HP, Bao ZY, et al
Virol Sin. 2010 Oct;25(5):316-28.
Abstract

Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing
regimen: results from a randomized comparative trial: (Novavir ANRS 073).
Descamps D, Joly V, Flandre P
J Clin Virol. 2005 Jun;33(2):99-103.
Abstract

Detection of Drug-Resistant Minority Variants of HIV-1 During Virologic Failure of Indinavir,
Lamivudine, and Zidovudine.
Dykes C, Najjar J, Bosch RJ, et al
J Infect Dis. 2004 Mar 15;189(6):1091-6.
Abstract

Drug resistance in patients experiencing early virological failure under a triple combination
including indinavir.
Gallego O, de Mendoza C, Perez-Elias MJ, et al.
AIDS 2001 Sep 7;15(13):1701-1706
Abstract

Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of
indinavir, ritonavir and saquinavir.
Taylor S, Back DJ, Drake SM, et al.
J Antimicrob Chemother 2001 Sep;48(3):351-4
Abstract

Adherence

Assessment of adherence to triple antiretroviral treatment including indinavir: role of the
determination of plasma levels of indinavir.
Alcoba M, Cuevas MJ, Perez-Simon MR
J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):253-8.
Abstract

Treatment Strategies

Cryptococcus

Indinavir-treated Cryptococcus neoformans promotes an efficient antifungal immune
response in Immunosuppressed hosts.
Pericolini E, Cenci E, Monari C, et al
Med Mycol. 2006 Mar;44(2):119-26.
Abstract

Influence of Indinavir on Virulence and Growth of Cryptococcus neoformans.
Monari C, Pericolini E, Bistoni G, et al
J Infect Dis. 2005 Jan 15;191(2):307-11
Abstract

Cryptosporidiosis

Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo
models.
Mele R, Morales MA, Tosini F, Pozio E.
Int J Parasitol. 2003 Jul;33(7):757-764.
Abstract

HIV/TB

Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin treated
HIV/tuberculosis co-infected patients: a pilot study.
Avihingsanon A, van der Lugt J, Singphore U, et al
AIDS Res Hum Retroviruses. 2012 Jan 17.
Abstract

Kaposi's Sarcoma

Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the
HIV protease inhibitor indinavir.
Monini P, Sgadari C, Grosso MG, et al
AIDS. 2009 Jan 22
Abstract

Toxicity

Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related
toxicity.
Wasmuth JC, Lambertz I, Voigt E, et al
Eur J Clin Pharmacol. 2007 Aug 10;
Abstract

The use of pharmacokinetically guided indinavir dose reductions in the management of
indinavir-associated renal toxicity.
Boyd MA, Siangphoe U, Ruxrungtham K, et al
J Antimicrob Chemother. 2006 Apr 4;
Abstract

Indinavir Main Page Main New/Newsworthy Home Page

Indinavir Journal Citations